Starwatch: sanguine Antares contrasts with silver light of the moon
Summer in the UK and similar northern latitudes is the best time of year to catch sight of the zodiacal constellation Scorpius, the scorpion. The constellation contains the beautiful star Antares. Shining blood-red just above the southern horizon, Antares is a prize well worth tracking down and this week, the moon helps point it out.
The chart shows the view looking south from London at 23:00 BST on 9 June. The moon will be cruising through the constellation and Antares will be unmistakable, its sanguine hues contrasting beautifully with the silver light of the Earth's natural satellite.
Technically, the moon will still be in its waxing gibbous phase but with 98% of its visible surface illuminated, in practice it will appear to us as essentially a full moon.
Antares itself is the 15th brightest star in the night sky. Situated about 550 light years from Earth, it contains about 15 times the mass of the sun, is about 680 times the size, and pours out almost 76,000 times more energy.
From the southern hemisphere, around mid-evening, Antares and Scorpius appear high in the eastern sky. From Sydney on 10 June, the moon and Antares will be side by side.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Scorpion, fresh off Lilly deal, spins out startup Antares
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Fresh off a multibillion-dollar deal with Eli Lilly, cancer drug startup Scorpion Therapeutics is trying for an encore, debuting a successor company on Tuesday that's carrying forward much of its previous work. Called Antares Therapeutics, the startup is launching with $177 million in financing from nearly a dozen investors, among them previous backers Omega Funds and Atlas Venture. Antares will use that cash to advance a group of small molecule drugs Scorpion had been working on, as well as programs the company had been advancing through a 2022 partnership with AstraZeneca. Its work will specifically focus on cancer and other unspecified 'serious diseases,' according to a statement. The company didn't divulge more details about its pipeline, only noting on its website that its first program should begin human testing in 2026 and multiple others are in preclinical development. In a statement, CEO Adam Friedman, who previously ran Scorpion, said the company's research is "fueled by discoveries in drugging previously inaccessible targets.' Antares could also get future milestone payments and royalties from a pair of cancer drugs involved in a Scorpion alliance with Pierre Fabre Laboratories. Another startup, Moma Therapeutics, has rights to a PARP inhibitor Scorpion was advancing, too. Scorpion was co-founded in 2020 by Gary Glick, who helped the company raise nearly $300 million in venture funding before departing in 2021. Prior to Scorpion, Glick led Lycera, which formed a 2015 deal with Celgene, and IFM Therapeutics, which has spun off multiple companies that were acquired by larger drugmakers. Glick went on to lead inflammatory drug developer Odyssey Therapeutics, which has been trying to go public. In the meantime, Scorpion was helmed by Friedman, who helped the company raise additional funding, form multiple partnerships and generate six cancer drug candidates, three of which are in clinical testing, according to its statement. Scorpion sold one, dubbed STX-678, to Eli Lilly in January for as much as $2.5 billion. As part of that deal, it formed a new company holding its other assets and inheriting its employees. That company, now known as Antares, is supported by Scorpion's old shareholders and also led by Friedman. 'Antares will build on what Scorpion started: combining cutting edge computational and experimental chemistry and biology with laser-focused clinical development,' said Keith Flaherty, a board member and director of clinical research at Massachusetts General Hospital Cancer Center, in a statement. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 hours ago
- Yahoo
Photos: Strawberry Moon wows across the world
June's Strawberry Moon put on a show around the world with a slight berry hue and a view low on the horizon for the first time since last summer. The Strawberry Moon reached peak illumination around 3 a.m. on Wednesday and appeared full and bright on Tuesday evening. The video at the top of this story was taken on Tuesday from Chicago, where the lucky photographer captured a helicopter and plane passing in front of the glowing Moon. The final full Moon of spring is named the Strawberry Moon for the time when the berries are ripe for picking and also the slight reddish hue because it is lower in the sky. "When it spends more of that time in that lower portion of the sky, you're looking through more of Earth's atmosphere, which makes these moons generally look redder and more golden," said Dr. Tyler Richey-Yowell, a postdoctoral fellow at Lowell Observatory in Arizona. This golden glow was on display Tuesdsay night in New York City, where the Empire State Building and the Moon made a beautiful pair. How To Photograph The Moon With Your Phone In Florida, SpaceX's Falcon 9 rocket and Dragon spacecraft presented a trifecta of space with the Moon looming large in the night sky. Saharan dust moving up the Southeast coast could have contributed to the yellow and orange tint of the Moon on Tuesday. Wildfire smoke provided an added boost to the red coloring of the Moon in Columbus, Ohio, as the image below shows. In the United Kingdom, the Moon appeared berry red near the northeast coast of England along Whitley Bay. A golden Moon appeared peaking out from behind the mausoleum of Mustafa in Turkey on Tuesday in the creatively set image article source: Photos: Strawberry Moon wows across the world
Gizmodo
4 hours ago
- Gizmodo
These Are the Dogs Most Likely to Get Diarrhea
Researchers in the U.K. analyzed vet records from over two million dogs to uncover the messy truth about canine diarrhea. Speaking from personal experience; fewer things in the world are messier than a dog with the runs. New research out today reveals how often people will take their dog to the vet for a bout of diarrhea, as well as some potential factors that could raise a pup's risk of it, such as their breed. Scientists at the Royal Veterinary College in the U.K. conducted the study, which examined the vet records of several million dogs. They estimated that one in every 12 dogs experiences diarrhea serious enough to prompt a vet visit each year, with certain breeds, including German Shepherds, more likely to experience it. The study also suggests that dogs are often getting overprescribed antibiotics as a result. Much like their human owners, dogs commonly suffer from diarrhea, and the study's researchers wanted to better understand how often it's diagnosed in primary care vet clinics and how it's typically managed. To do so, they analyzed the (anonymous) medical records of more than two million U.K. dogs that visited vets in 2019. They also studied the characteristics of 1,835 randomly selected cases of confirmed diarrhea within this sample. They calculated that 8.18% of dogs are diagnosed with diarrhea by their primary vet in a given year. But this risk was higher for six breeds in particular compared to the average mixed breed dog: the Maltese, Miniature Poodle, Cavapoo, German Shepherd, and Yorkshire Terrier. Conversely, only two breeds—the Jack Russell Terrier and Chihuahua—had a lower risk of diarrhea. Dogs younger than three and older than nine were also more likely to be diagnosed with diarrhea compared to middle-aged dogs. About a third of the cases they studied involved blood in the stool, a sign of more serious illness; nearly half of all dogs studied also experienced vomiting. But most cases in general cleared up without too much trouble, with more than 80% only meriting a single trip to the vet. In other words, as is true with people, doggy diarrhea is usually miserable but short-lasting. 'Experiencing the dreaded doggy poonami is one of those events every dog owner fears. This new study shows that diarrhea events are very common in dogs but that owners should not panic—no matter how bad the deluge, most dogs will recover in a few days with good veterinary treatment,' said lead study researcher Dan O'Neill, an associate professor of companion animal epidemiology at the RVC, in a statement provided to Gizmodo. The findings might also provide some insights into the nature of doggy diarrhea. It's possible that the higher-risk breeds highlighted in the study are more genetically vulnerable to digestive problems, for instance. The researchers also found other factors tied to a higher diarrhea risk, such as scavenging (the tendency for a dog to try eating things off the ground or from other non-intentional sources). On the more worrying side, the findings indicate that antibiotics are getting overused in dogs as well as humans. Veterinary guidelines have long advised against using antibiotics for mild to moderate cases of diarrhea in dogs, the researchers note. These drugs are not only unlikely to speed up a dog's recovery, but can incidentally increase antibiotic resistance. Despite these guidelines, however, nearly 40% of the cases they studied were still treated with antibiotics. 'High antibiotic use within veterinary clinical management against years of recommendation to the contrary raises concerns about unnecessary antibiotic therapy for this condition,' the researchers wrote in their paper, published in PLOS ONE. Dogs deserve nothing but the best healthcare, of course. But for most cases of diarrhea, time and less intrusive measures like switching to blander foods (boiled chicken, white rice, etc.) are all you need to help your dog through their gastrointestinal ordeal.
